That msg above was to you mate, forgot to click reply

First 51 Last

Share
Profile

Follow
Bilson

594 Posts.

114

14/02/19

23:07

Post #: 37443190
Share

Originally posted by BigDaniel: ↑

I'm seeing this deal with BioHealth as the best development from CGB to yet.

The company has made some extremely good partnerships to date but the BioHealth binding-MOU allows the amalgamation of all these deals improving CGB's prospects of short term revenue.

If I had to pick either the Medcann acquisition or the BioHealth MOU it's BioHealth hands down.

The finer detail of how CGB..BioHealth & Medcann will all tie in together is not yet available or immediately obvious to shareholders.

Based on the information available my personal preference would be for CGB to still aquire Medcann under the original proposal. The only difference then being is our funds raised from the cr are diverted to the BioHealth project, the facility fit-out could then be completed at a later date.

I have absolute faith in management & CGB's prospects but the 250,000,000 dilution for Medcann is absolutely worth it imo.

I think it's important to understand a companies position before criticism.

I know talking about reality is not always a popular topic on this forum however the truth lies somewhere between the biggest optimists & the pessimistic down rampers.

Fact is CGB has more shares on issue than desirable..Pursuing bauxite for numerous years will do that..Dilution is part & parcel of prospecting.

When you take shares on issue & cash available into consideration it greatly restricts a companies options to develop their business model into something viable & rewarding for shareholders whilst keeping these two health indicators in check.

CGB have been masterful in navigating from bauxite prospectors to potential hemp & medicinal marijuana leaders in Australia & abroad.

In short Sholom & team have made fantastic use of what they had to work with which was more shares on issue than desirable & next to no assets to leverage! The healthy bank balance has been a real highlight for potential investors like myself, despite the potential rewards I probably would not have invested if not for that fat in the bank vs expenditure as of late 2017.

I'll maintain my view..Give the company the reasonable amount of time to perfect their harvests & materialize partnerships & big rewards will be had.

Extremely interesting & exciting times over the next 12 months.

Expand

That msg above was to you mate, forgot to click reply

CGB Price at posting: 3.7¢ Sentiment: Sell Disclosure: Not Held
Upvote

0 Great analysis

Reply

Top Stories

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

HMI

Global Lithium up 13% as it joins the ranks of battery metal players pivoting to gold

Breaking news: New opportunities for investors & companies - HotCopper opens to capital raising!

OAR

Chris Judd's Talk Ya Book: Orthocell building on 'enormous potential' with steady growth - and US push to come

ACW

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

There are more pages in this discussion • 47 more messages in this thread...

First 51 Last

Add CGB (ASX) to my watchlist

That msg above was to you mate, forgot to click reply

Top Stories

History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025

Global Lithium up 13% as it joins the ranks of battery metal players pivoting to gold

Breaking news: New opportunities for investors & companies - HotCopper opens to capital raising!

Chris Judd's Talk Ya Book: Orthocell building on 'enormous potential' with steady growth - and US push to come

This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game

Featured News